Breaking News Instant updates and real-time market news.

2019-02-12 07:55:01

HSIC

Henry Schein

$60.38

1.26 (2.13%)

07:55

02/12/19

02/12

07:55

02/12/19

07:55

Henry Schein price target lowered to $69 from $85 at RBC Capital

RBC Capital analyst Stephen Hagan lowered his price target on Henry Schein to $69 to reflect his updated model after the company's animal health business spin-off. The analyst notes that the spin-off has made shares more attractive, but sees the 18-times forward earnings multiple assumed in his price target as a hurdle to a more positive rating on the shares. Hagan also keeps his Sector Perform rating on Henry Schein.

20

Feb

HSICHenry Schein

$60.38

1.26 (2.13%)

01/02/19

01/02/19DOWNGRADE

Fly Intel: Top five analyst downgrades

Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Henry Schein (HSIC) downgraded to Neutral from Outperform at Baird with analyst Jeff Johnson saying he is more cautious on the combination of the dental sector's secular overhangs, softer Q4 patient volume checks, and accelerating equipment pricing pressures. 2. Conagra Brands (CAG) downgraded to Buy from Conviction Buy at Goldman Sachs with analyst Jason English saying while the stock's 41% decline since October 23 is overdone, the "path of recovery is likely to be protracted." 3. BioMarin (BMRN) downgraded to Market Perform from Outperform at Raymond James with analyst Laura Chico saying BioMarin lacks near-term catalysts which makes it more vulnerable in a "risk off" environment. 4. Hologic (HOLX) downgraded to Underweight from Equal Weight at Morgan Stanley with analyst David Lewis saying his checks with about 40 medspas highlighted market saturation of body sculpting devices. 5. Louisiana-Pacific (LPX) downgraded to Neutral from Buy at BofA/Merrill with analyst George Staphos citing the steep drop-off in 2H 2018 panel pricing and challenging 1H 2019 comparisons versus 1H 2018. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

01/03/19

EVER

01/03/19DOWNGRADEEVERUnderperform

Henry Schein downgraded to Underperform from In Line at Evercore ISI

01/03/19

EVER

01/03/19DOWNGRADEEVERUnderperform

Henry Schein downgraded to Underperform at Evercore ISI

As previously reported, Evercore ISI downgraded Henry Schein to Underperform from In Line. Analyst Ross Muken remains negative on the Dental complex given long-term risks to margins due to pricing, competition, and disintermediation. Muken expects a moderation in the company's share gains in consumables/high-tech equipment, and said the CVET spin is near completion with underling profit likely lower short-term.